BGC20‐1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache
Open Access
- 1 January 2009
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 156 (2), 316-327
- https://doi.org/10.1111/j.1476-5381.2009.00027.x
Abstract
Background and purpose: Prostanoid EP4 receptor antagonists may have therapeutic utility in the treatment of migraine since EP4 receptors have been shown to be involved in prostaglandin (PG)E2-induced cerebral vascular dilatation, which may be an important contributor to migraine pain. This study reports the pharmacological characterization of BGC20-1531, a novel EP4 receptor antagonist. Experimental approach: BGC20-1531 was characterized in radioligand binding and in vitro functional assays employing recombinant and native EP4 receptors. Changes in canine carotid haemodynamics were used to assess the pharmacodynamic profile of BGC20-1531 in vivo. Key results: BGC20-1531 exhibited high affinity at recombinant human EP4 receptors expressed in cell lines (pKB 7.6) and native EP4 receptors in human cerebral and meningeal artery (pKB 7.6–7.8) but showed no appreciable affinity at a wide range of other receptors (including other prostanoid receptors), channels, transporters and enzymes (pKi < 5). BGC20-1531 competitively antagonized PGE2-induced vasodilatation of human middle cerebral (pKB 7.8) and meningeal (pKB 7.6) arteries in vitro, but had no effect on responses induced by PGE2 on coronary, pulmonary or renal arteries in vitro. BGC20-1531 (1–10 mg·kg−1 i.v.) caused a dose-dependent antagonism of the PGE2-induced increase in canine carotid blood flow in vivo. Conclusions and implications: BGC20-1531 is a potent and selective antagonist at EP4 receptors in vitro and in vivo, with the potential to alleviate the symptoms of migraine that result from cerebral vasodilatation. BGC20-1531 is currently in clinical development for the treatment of migraine headache.This publication has 59 references indexed in Scilit:
- Cortical spreading depression (CSD)Der Schmerz, 2008
- Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraineNeurology, 2008
- Guide to Receptors and Channels (GRAC), 3rd editionBritish Journal of Pharmacology, 2008
- Efficacy of Rizatriptan 10 mg Administered Early in a Migraine AttackHeadache: The Journal of Head and Face Pain, 2006
- Early intervention in migraine with sumatriptan tablets50 mg versus 100 mg: A pooled analysis of data from six clinical trialsClinical Therapeutics, 2005
- Prostaglandin E2Inhibits the Phospholipase D Pathway Stimulated by Formyl-methionyl-leucyl-phenylalanine in Human Neutrophils. Involvement of EP2Receptors and Phosphatidylinositol 3-kinase γMolecular Pharmacology, 2004
- EP4 prostanoid receptor‐mediated vasodilatation of human middle cerebral arteriesBritish Journal of Pharmacology, 2004
- Molecular mechanisms of diverse actions of prostanoid receptorsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1995
- Increase in PGE2 and TXA2 in the Saliva of Common Migraine Patients. Action of Calcium Channel BlockersHeadache: The Journal of Head and Face Pain, 1989
- Relevance of Prostaglandins in True Menstrual MigraineHeadache: The Journal of Head and Face Pain, 1989